Lung Cancer Management (LCM)

The strong link between smoking rates and lung cancer incidence has resulted in varying rates of disease within different populations whether on a geographic, socioeconomic or gender basis. What is clear is that, in spite of declining disease rates among some groups in certain developed countries, the disease remains a highly significant global burden. For example, the National Institute of Health estimates that cancer care cost the United States an overall $124.6 billion in 2010, $12.1 billion of which was due to lung cancer. Surgery, radiotherapy and chemotherapy – alone or in combination – all have a role to play in the treatment of lung cancer. Lung Cancer Management addresses key issues and current understanding in the diagnosis, staging and treatment of disease by exploring the best patient-centered clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in the clinic.

Lung Cancer Management (LCM) is :-

• International, Peer-Reviewed, Open Access, Refereed, Biological therapies, Biomarkers, Clinical trials, Comparative effectiveness, Molecular diagnostics, Risk and prevention, Surgical approaches , Online or Print , Continuously Journal

• UGC Approved, ISSN Approved: P-ISSN P-ISSN: 1758-1966, E-ISSN: 1758-1974, Established: 2012, Impact Factor: 0.9
• Provides Crossref DOI

• Not indexed in Scopus, WoS, DOAJ, PubMed, UGC CARE